World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
84
Citations
37231
World Ranking
14864
National Ranking
208

Overview

Albert Oriol is affiliated with the Autonomous University of Barcelona in Spain. Their research primarily focuses on the fields of medicine and biochemistry, genetics, and molecular biology. Within these broader disciplines, their work concentrates notably on hematology, oncology, molecular biology, genetics, and radiology, nuclear medicine and imaging.

The scientist's main topics of research include multiple myeloma research and treatments, protein degradation and inhibitors, peptidase inhibition and analysis, CAR-T cell therapy research, cancer treatment and pharmacology, monoclonal and polyclonal antibodies research, and chronic lymphocytic leukemia research.

Frequent co-authors collaborating with Albert Oriol are María-Victoria Mateos, Jesús F. San Miguel, Paula Rodríguez-Otero, Joaquin Martínez-López, and Laura Rosiñol.

Albert Oriol has published extensively in several scientific venues. The most frequent journals include Clinical Lymphoma Myeloma & Leukemia, Blood, Journal of Clinical Oncology, HemaSphere, and Blood Cancer Journal.

Several recent papers include:

  • Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma, 2021, New England Journal of Medicine
  • Teclistamab in Relapsed or Refractory Multiple Myeloma, 2022, New England Journal of Medicine
  • Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma, 2023, New England Journal of Medicine
  • Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma, 2022, New England Journal of Medicine
  • Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial, 2021, The Lancet

Best Publications

  • Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

    Nikhil C Munshi;Larry D Anderson;Nina Shah;Deepu Madduri

  • Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

    Meletios A. Dimopoulos;Albert Oriol;Hareth Nahi;Jesus San-Miguel

  • Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

    Hagop M. Kantarjian;Xavier G. Thomas;Anna Dmoszynska;Agnieszka Wierzbowska

  • Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

    Jesús Fernando San Miguel;Jesús Fernando San Miguel;Katja Weisel;Philippe Moreau;Martha Lacy

  • Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

    Meletios Athanasios Dimopoulos;Philippe Moreau;Antonio Palumbo;Douglas Edgar Joshua

  • Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

    Sagar Lonial;Brendan M Weiss;Saad Z Usmani;Seema Singhal

  • Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma

    Lotfi Benboubker;Meletios Athanasios Dimopoulos;Angela Dispenzieri;John Catalano

  • Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma

    María-Victoria Mateos;Miguel-Teodoro Hernández;Pilar Giraldo;Javier de la Rubia

  • Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial

    María-Victoria Mateos;Albert Oriol;Joaquín Martínez-López;Norma Gutiérrez

  • Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.

    Laura Rosiñol;Albert Oriol;Ana Isabel Teruel;Dolores Hernández

  • Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study

    María-Victoria Mateos;María-Victoria Mateos;José-M. Hernández;José-M. Hernández;Miguel-T. Hernández;Miguel-T. Hernández;Norma-C. Gutiérrez;Norma-C. Gutiérrez

  • Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

    Joaquin Martinez-Lopez;Juan J. Lahuerta;François Pepin;Marcos González

  • Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial

    Meletios A. Dimopoulos;Hartmut Goldschmidt;Ruben Niesvizky;Douglas Joshua

  • High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

    Bruno Paiva;Norma C. Gutiérrez;Laura Rosiñol;María-Belén Vídriales

  • Comparison of the Results of the Treatment of Adolescents and Young Adults With Standard-Risk Acute Lymphoblastic Leukemia With the Programa Español de Tratamiento en Hematología Pediatric-Based Protocol ALL-96

    Josep-María Ribera;Albert Oriol;Miguel-Angel Sanz;Mar Tormo

  • Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group

    Albert Oriol;Susana Vives;Jesús-María Hernández-Rivas;Mar Tormo

  • Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

    S. K. Kumar;M. A. Dimopoulos;E. Kastritis;E. Terpos

  • Treatment of High-Risk Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia in Adolescents and Adults According to Early Cytologic Response and Minimal Residual Disease After Consolidation Assessed by Flow Cytometry: Final Results of the PETHEMA ALL-AR-03 Trial

    Josep-Maria Ribera;Albert Oriol;Mireia Morgades;Pau Montesinos

  • Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials

    Juan-Jose Lahuerta;Bruno Paiva;Maria-Belen Vidriales;Lourdes Cordón

  • Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial

    María-Victoria Mateos;Albert Oriol;Joaquín Martínez-López;Norma Gutiérrez

Frequent Co-Authors

Maria-Victoria Mateos
Maria-Victoria Mateos University of Salamanca
Joan Bladé
Joan Bladé University of Barcelona
Juan José Lahuerta
Juan José Lahuerta Complutense University of Madrid
Jesús F. San Miguel
Jesús F. San Miguel University of Navarra
Josep-Maria Ribera
Josep-Maria Ribera Autonomous University of Barcelona
Meletios A. Dimopoulos
Meletios A. Dimopoulos National and Kapodistrian University of Athens
Ramón García-Sanz
Ramón García-Sanz University of Salamanca
Philippe Moreau
Philippe Moreau University of Nantes
Michele Cavo
Michele Cavo University of Bologna
Paul G. Richardson
Paul G. Richardson Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re interested in healthcare but are still exploring your options, there are several online degree paths and career pathways beyond traditional medical school. Many students consider alternative programs such as direct msn programs online. These are ideal for non-nursing graduates seeking a direct route to a Master’s in Nursing, making it possible to join the healthcare field without a prior nursing degree.

Entry-level roles in nursing are also in high demand. For those with little or no prior experience, accredited online adn programs for non nurses offer a convenient pathway toward becoming a Registered Nurse (RN). Additionally, not all programs require rigorous entrance exams. Prospects can explore whether do you have to take a teas test for lpn is mandatory for their desired program.

For those interested in the administrative side of healthcare, there are reputable medical billing and coding online schools that can lead to in-demand career opportunities working behind the scenes. Each of these flexible online programs offers a unique route to a rewarding healthcare career, with varying requirements and outcomes depending on your interests and past education.

Best Scientists Citing Albert Oriol

Trending Scientists

Recently Published Articles